Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 03:20:00 14/02/26 am AEDT			5-day change	1st Jan Change
310.60 ^DKK	+1.32%		+5.11%	-4.50%

14/02	Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows	RE
14/02	Novo Nordisk's Wegovy Tablet Reaches 38,000 New Prescriptions in the US	FW

Novo Nordisk to launch Ozempic pill in the U.S. in Q2 2026

Published on 02/05/2026 at 06:28 am AEDT

Reuters

Latest news about Novo Nordisk A/S

14/02	Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows	RE
14/02	Novo Nordisk's Wegovy Tablet Reaches 38,000 New Prescriptions in the US	FW
14/02	Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows	RE
14/02	Novo's Wegovy pill tracks over 38,000 prescriptions in fifth week	RE
13/02	Biocon aims for revenue surge with rollout of generic weight-loss drugs	RE
13/02	US prescriptions for Novo's Wegovy pill were 38,220 (not '38,909') for week ended Feb 6 - IQVIA data shared by analyst shows	RE
13/02	NOVO NORDISK : Barclays reiterates its Neutral rating	ZD
13/02	PriorNilsson Yield Down 0.79 Percent in January – Tougher Start to 2026	FW
13/02	US could take action including fines against Hims after brief Wegovy copy launch	RE
13/02	PriorNilsson Sverige Aktiv Up 3.26 Percent in January – Optimistic Start	FW
13/02	Barclays Lowers Price Target for Novo Nordisk to 340 Danish Kroner (from 360), Reiterates Equal Weight - BN	FW
13/02	Novo Nordisk Estimates Updated as Berenberg Notes 'Cautious' FY26 Guidance; Price Target Down	MT
13/02	AlphaValue/Baader Europe Cuts Novo Nordisk Price Target, Forecasts Amid Outlook Downgrades, Competitive Pressures	MT
13/02	Sector Update: Health Care Stocks Rise Late Afternoon	MT
13/02	Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

69,150

Sector

Pharmaceuticals

Calendar

27/03 - Annual General Meeting

More about the company